We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+15.71%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.92B
AUM Growth
+$466M
Cap. Flow
-$28.9M
Cap. Flow %
-0.49%
Top 10 Hldgs %
26.27%
Holding
163
New
16
Increased
58
Reduced
30
Closed
24

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$87.6M
2
GH icon
Guardant Health
GH
+$61.3M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$37.2M
4
TOST icon
Toast
TOST
+$32M
5
LAD icon
Lithia Motors
LAD
+$28.4M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$71.9M
2
DOCS icon
Doximity
DOCS
+$45M
3
ENPH icon
Enphase Energy
ENPH
+$36M
4
ROP icon
Roper Technologies
ROP
+$31.6M
5
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$31.6M

Sector Composition

Rank Sector Weight
1 Healthcare 43.76%
2 Technology 22.95%
3 Industrials 13.17%
4 Consumer Discretionary 7.97%
5 Utilities 3.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FANG icon
101
Diamondback Energy
FANG
$56.2B
$14.9M 0.25%
+113,753
New +$15.2M
BEAM icon
102
Beam Therapeutics
BEAM
$2.73B
$14.7M 0.25%
459,203
– –
MSCI icon
103
MSCI
MSCI
$41.9B
$14.3M 0.24%
+30,415
New +$14.8M
BMRN icon
104
BioMarin Pharmaceuticals
BMRN
$11.7B
$14.2M 0.24%
164,299
– –
SYY icon
105
Sysco
SYY
$40.6B
$14.2M 0.24%
191,333
– –
SRPT icon
106
Sarepta Therapeutics
SRPT
$1.64B
$14M 0.24%
122,643
-64,625
-35% -$8.33M
BCRX icon
107
BioCryst Pharmaceuticals
BCRX
$2.35B
$13.9M 0.23%
1,970,000
+867,111
+79% +$6.96M
GXO icon
108
GXO Logistics
GXO
$5.8B
$13.8M 0.23%
220,162
+87
+0% +$4.88K
VRSK icon
109
Verisk Analytics
VRSK
$26.1B
$13.8M 0.23%
61,076
-140,013
-70% -$29.4M
RCM
110
DELISTED
R1 RCM Inc. Common Stock
RCM
$13.6M 0.23%
735,705
+140,136
+24% +$2.28M
DVAX
111
DELISTED
Dynavax Technologies
DVAX
$13.3M 0.22%
+1,026,086
New +$11.7M
IEX icon
112
IDEX
IEX
$17.3B
$13.2M 0.22%
61,154
– –
EHC icon
113
Encompass Health
EHC
$11B
$12.9M 0.22%
189,979
– –
NBIX icon
114
Neurocrine Biosciences
NBIX
$18.7B
$12.7M 0.22%
135,000
– –
ETNB
115
DELISTED
89bio
ETNB
$12.2M 0.21%
642,073
– –
VKTX icon
116
Viking Therapeutics
VKTX
$3.84B
$12.2M 0.21%
+750,000
New +$15.7M
ESI icon
117
Element Solutions
ESI
$8.68B
$11.5M 0.19%
598,608
-94,948
-14% -$1.75M
OKUR
118
OnKure Therapeutics
OKUR
$162M
$11.5M 0.19%
+175,000
New +$14.1M
MASS icon
119
908 Devices
MASS
$313M
$9.82M 0.17%
1,430,995
-799,670
-36% -$6.43M
RVMD icon
120
Revolution Medicines
RVMD
$40.9B
$9.65M 0.16%
+360,635
New +$8.85M
DNLI icon
121
Denali Therapeutics
DNLI
$3.86B
$9.25M 0.16%
313,407
– –
NDAQ icon
122
Nasdaq
NDAQ
$53.2B
$9.11M 0.15%
182,708
-205,893
-53% -$11.2M
PTGX icon
123
Protagonist Therapeutics
PTGX
$8.92B
$8.84M 0.15%
+320,000
New +$8.01M
CRNX icon
124
Crinetics Pharmaceuticals
CRNX
$8.85B
$7.83M 0.13%
434,768
– –
EQIX icon
125
Equinix
EQIX
$103B
$7.47M 0.13%
+9,524
New +$6.97M
3 4
5
6 7

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Eventide Asset Management held 163 positions worth $5.92B, up 8.6% from $5.45B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management's Q2 2023 filing shows 16 new, 58 increased, 30 reduced and 24 closed positions. Its largest new stake was Toast: 1,603,866 shares worth $36.2M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $71.9M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 43% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q2 2023 buy was Toast: 1,603,866 shares worth $36.2M.
  • Eventide Asset Management added most to Zentalis Pharmaceuticals in Q2 2023, an estimated $87.6M increase.
  • Eventide Asset Management's biggest Q2 2023 reduction was Doximity, cutting an estimated $45M.
  • Eventide Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $71.9M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $5.92B portfolio in Q2 2023.
  • Eventide Asset Management opened 16 new positions and closed 24 in Q2 2023.
  • Eventide Asset Management's portfolio value rose 8.6% quarter-over-quarter to $5.92B.

Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.